<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2175">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01598506</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00054701</org_study_id>
    <nct_id>NCT01598506</nct_id>
  </id_info>
  <brief_title>Intrathecal Hydromorphone for Labor Analgesia</brief_title>
  <official_title>Determination of the ED50 of Intrathecal Hydromorphone in Laboring Women Using the Up-and-down Sequential Allocation Method</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the dose of hydromorphone which will relieve the pain of women
      in labor when delivered directly in the area around the spinal cord (i.e., intrathecal
      injection). The primary objective is to determine the dose of intrathecal hydromorphone that
      results in a pain score of less than 3 out of 10 thirty minutes after intrathecal injection
      in 50% of women. Secondary objectives include determining this dose at five and ten minutes
      after injection. Thirty women admitted to labor and delivery for planned vaginal delivery
      desiring epidural placement will be consented for the study. The starting dose of
      intrathecal hydromorphone will be 6 mcg. The up-and-down sequential allocation method of
      statistical analysis will be used, meaning that each subsequent dose will be dependent upon
      the result obtained from the prior dose - ergo, if the initial subject has pain relief, the
      second subject will receive 4 mcg (2 mcg less), but if the initial subject does not have
      pain relief, the second subject will receive 8 mcg (2 mcg more) of hydromorphone.

      After the intrathecal injection is given and the epidural is placed, visual analogue pain
      scores will be assessed 60 minutes following injection. A pain score of less than three will
      be a positive result. A pain score of three or greater will be a negative result. Blood
      pressure, heart rate, arterial oxygen saturation, fetal heart rate, and any side effects
      will also be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Pain Score</measure>
    <time_frame>Baseline, 30 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in pain score was calculated by subtracting the 30 minute pain score from the baseline pain score.The pain scores were on a continuous visual analogue scale of 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores, Visual Analogue Pain Scale</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score, Visual Analogue Pain Scores</measure>
    <time_frame>30 minutes after intrathecal injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Labor Pain</condition>
  <arm_group>
    <arm_group_label>Hydromorphone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laboring patients receive ED50 of hydromorphone one time intrathecally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <description>Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.</description>
    <arm_group_label>Hydromorphone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy patients

          -  Labor

          -  Desires pain relief

        Exclusion Criteria:

          -  Any comorbidities other than obesity
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grant C Lynde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>November 4, 2014</lastchanged_date>
  <firstreceived_date>May 10, 2012</firstreceived_date>
  <firstreceived_results_date>November 4, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Grant Lynde</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Labor Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects enrolled from January 2013 to November 2013</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hydromorphone</title>
          <description>Laboring patients receive ED50 of hydromorphone one time intrathecally.
ED50 of hydromorphone was 12.7 mcg +/- 3.27.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hydromorphone</title>
          <description>Laboring patients receive ED50 of hydromorphone one time intrathecally.
ED50 of hydromorphone was 12.7 mcg +/- 3.27.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Score</title>
        <description>Change in pain score was calculated by subtracting the 30 minute pain score from the baseline pain score.The pain scores were on a continuous visual analogue scale of 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
        <time_frame>Baseline, 30 minutes</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>Laboring patients receive ED50 of hydromorphone one time intrathecally.
ED50 of hydromorphone was 12.7 mcg +/- 3.27.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Pain Score</title>
            <description>Change in pain score was calculated by subtracting the 30 minute pain score from the baseline pain score.The pain scores were on a continuous visual analogue scale of 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-4.13" lower_limit="-8" upper_limit="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores, Visual Analogue Pain Scale</title>
        <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>Laboring patients receive ED50 of hydromorphone one time intrathecally.
ED50 of hydromorphone was 12.7 mcg +/- 3.27.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pain Scores, Visual Analogue Pain Scale</title>
            <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8.57" lower_limit="7" upper_limit="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score, Visual Analogue Pain Scores</title>
        <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
        <time_frame>30 minutes after intrathecal injection</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone</title>
            <description>Laboring patients receive ED50 of hydromorphone one time intrathecally.
ED50 of hydromorphone was 12.7 mcg +/- 3.27.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pain Score, Visual Analogue Pain Scores</title>
            <description>Continuous Visual Analogue Scale 0 - 10 (0=no pain, 10=worst imaginable pain).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.43" lower_limit="0" upper_limit="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hydromorphone</title>
          <description>Laboring patients receive ED50 of hydromorphone one time intrathecally.
ED50 of hydromorphone was 12.7 mcg +/- 3.27.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Grant Lynde</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-3900</phone>
      <email>glynde@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
